TEST:

LiquidPlex™

The panel size was increased by 300% and had negligible impact on performance and cross-reactivity of the probes implying high multiplexing capabilities. Taken together, Bridge Capture is a cost-efficient, simple, rapid and sensitive cancer diagnostics tool that has a potential to significantly improve the detection of mutations.

LBG reduces the time to genomic diagnosis in patients with newly diagnosed NSCLC compared to tissue genotyping, identifies actionable variants not reported in tissue, and results in overall cost savings.

Of the biliary tract cancer cases examined with this method, 13 (54%) and 4 (17%) resulted in positive cancer driver mutation detection in the bile and plasma cfDNAs, respectively. These results suggest that bile is a more reliable source for LB than plasma for multigene panel analyses of biliary tract cancers.

Frequent liquid biopsies are useful for identifying known EGFR mutations as markers for early detection of relapse. Several cancer driver mutations were observed, suggesting a variety of mechanisms of resistance in first-line osimertinib-treated lung adenocarcinoma.

The findings imply that a novel sequencing assay, modified to spike synthetic DNA and report in copies per mL better reflects natural plasma biomarker levels than does allele fraction calculation. This strategy may help overcome both natural and ex vivo pre-analytic interferences with cfDNA biomarker measurements, whether assayed by NGS or quantitative PCR. Clinical studies are needed to evaluate added benefits of reporting viral load or tumor burden in copies per mL beyond a more traditional fractional unit of measurement.

"Tecan has sued Invitae, ArcherDx, Integrated DNA Technologies, and Qiagen for allegedly infringing on patents related to nucleic acid enrichment and high-throughput sequencing methods...Tecan asserts in the first complaint that its technology underlies what Invitae, ArcherDx, and IDT refer to as their Anchored Multiplex PCR (AMP) target enrichment technology, which is found in Invitae's Personalized Cancer Monitoring (PCM) service and in ArcherDx's LiquidPlex, VariantPlex, and FusionPlex kits."

"The findings imply that a novel sequencing assay, modified to spike synthetic DNA and report in copies per mL better reflects natural plasma biomarker levels than does allele fraction calculation. This strategy may help overcome both natural and ex vivo pre-analytic interferences with cfDNA biomarker measurements, whether assayed by NGS or quantitative PCR. Clinical studies are needed to evaluate added benefits of reporting viral load or tumor burden in copies per mL beyond a more traditional fractional unit of measurement."

"Integrated DNA Technologies, Inc....announced it closed on the purchase of Next Generation Sequencing (NGS) research assays from Invitae Corporation (NYSE: NVTA) under the trademarked name Archer. The integration of IDT’s portfolio with the acquired NGS research assays—which have been foundational in researching novel cancer fusions—will empower labs with an all-in-one solution to uncover biomarkers and advance cancer discoveries. The transaction enables IDT to expand its existing operations, build upon the legacy Archer portfolio, and welcome more than 100 new associates globally....Transaction Details-IDT purchased Archer NGS research assays—which reported high double-digit growth since 2019—from Invitae for cash consideration of approximately $48 million, subject to certain adjustments. The transaction is structured as an asset deal and includes a license to intellectual property related to the AMP technology."

Comparing the mutational patterns of the matched samples, we found that only one cfDNA had the same mutations (KRAS, SMAD4 and TP53) in the paired tissue. The results of the comparison between tumor tissue DNA and matched plasma cfDNA underline the importance of studying the paired solid tumor and plasma samples together.

Seraseq ctDNA myeloid mutation mixes were demonstrated to provide reliable reference to 22 clinically relevant myeloid variants at VAFs from 1% down to 0.1%. These reference materials support ctDNA NGS assay development and routine quality control, and hence may be highly beneficial for the development of liquid biopsies for myeloid blood cancers without the need for flow cytometry. These reference materials can be used to monitor both sensitivity and specificity of variant detection using both dPCR and NGS-based assays.

Patients with detectable ctDNA prior to the start of first-line imatinib treatment had inferior outcome compared to patients without detectable ctDNA. ctDNA levels decreased in all patients after starting imatinib, but ctDNA dynamics was not associated with outcome. Primary and secondary mutations were detected at the time of disease progression, but not in samples collected prior to radiological progression.

The explainable AI algorithms suggested a negative predictive role of TP53 and KIT mutational status. More data are needed to improve the goodness of the algorithms.